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Abstract To determine whether there are differences in
the adverse effect profile between 1, 2 and 5% Lidocaine
when used for occipital nerve blocks (ONB) in patients
with occipital neuralgia. Occipital neuralgia is an uncom-
mon cause of headaches. Little is known regarding the
safety of Lidocaine injections for treatment in larger series
of patients. Retrospective chart analysis of all ONB was
performed at our headache clinic during a 6-year period on
occipital neuralgia patients. 89 consecutive patients with
occipital neuralgia underwent a total of 315 ONB. All the
patients fulfilled the IHS criteria for Occipital Neuralgia.
Demographic data were collected including age, gender,
and ethnicity. The average age of this cohort was
53.25 years, and the majority of patients were females 69
(78%). Ethnicity of patients was diverse, with Caucasian
48(54%), Hispanics 31(35%), and others 10 (11%). 69
patients had 1%, 18 patients had 2% and 29 patient were
given 5% Lidocaine. All Lidocaine injections were given
with 20 mg Depo-medrol and the same injection technique
and location were used for all the procedures. Eight
patients (9%)had adverse effects to the Lidocaine and
Depo-medrol injections, of which 5 received 5% and 3
received 1% Lidocaine. Majority of patients who had
adverse effects were female 7(87%), and had received
bilateral blocks (75%). ONB is a safe procedure with 1%
Lidocaine; however, caution should be exerted with 5% in
elderly patients, 70 or older, especially when administering
bilateral injections.
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Introduction
Occipital nerve blocks (ONB) have generated great interest
among headache specialists recently because of their
potential to treat many types of intractable headaches [1,
2]. Injections are performed by targeting the greater
occipital nerve (GON), derived from the dorsal ramus of
the second cervical nerve root, which exits the back of the
head. It is a relatively uncommon procedure, and recently
literature has been emerging on the efficacy of this pro-
cedure for various types of headaches. However, even less
is known about the adverse effect profile of this procedure.
Neuropathic pain in the back of the head along the distri-
bution of the occipital nerves is called Occipital neuralgia
[3] and one of the criteria for diagnosis is response to ONB.
Occipital neuralgia may be associated with migraine
headaches complicating the picture of a chronic daily
headache patient [4, 5].
In this study, we proposed to investigate whether there
were differences in the side effect profile between different
strengths of Lidocaine and whether there was a specific
population that was more likely to have side effects. To our
knowledge, this is the first study reporting on the side effect
profile of 5% Lidocaine for ONB in a large case series of
patients.
Methods
The study sample consisted of retrospective chart review of
89 consecutive patients presenting to our headache clinic at
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the University of California during 2005 to January 2010
with occipital neuralgia as determined by the International
headache society criteria (IHS). The IHS criteria for
occipital neuralgia include: (1) unilateral headache, con-
tinuous or paroxysmal, (2) diminished sensation or dyses-
thesia in the affected area, (3) circumscribed tenderness
over the GON as it crosses the superior nuchal line, (4)
relief of acute attack by local anesthetic blocks [6]. The
study was approved by the Institutional Review Board of
University of Southern California. Demographic data were
collected including age, gender, and ethnicity.
All procedures were done using the same landmarks and
technique. Injections were performed at the junction of
medial and middle thirds from a line drawn between the
mastoid process and the nuchal line and the procedure was
performed by the same clinician. Vital signs were taken
prior to the procedure. All patients had tenderness over
GON. Patients with adverse events (AEs) were monitored
after the procedure.
Statistical analysis
We defined a set of clinical and demographic factors that
may potentially be associated with AE and that were
available from chart review. Besides patient demographic
information (age, gender, and ethnicity), we collected data
on the location of ONB (whether unilateral or bilateral) and
the number of times ONB was given to each patient.
Samples t test was performed to determine correlation
analyses between Lidocaine dose and occurrence of AEs
and age. Chi-square test was performed to determine cor-
relation analyses between occurrence of AEs and non-
contiguous variables. All statistical testing was performed
at a two-sided 5% level of significance using Statistical
Analysis System version 11.1 (SAS Institute, Cary, NC).
Results
There was no difference in age, gender or ethnicity among
patients who received 1, 2 or 5% Lidocaine (Table 1). The
majority of patients were middle-aged females. Many of
our subjects received serial blocks over the 6-year period,
so the total number of blocks performed was much greater
than the total number of subjects. Five patients who
received Lidocaine 5% (5/111) and three patients who
received (3/173) Lidocaine 1% reported side effects
(Table 2). The majority of patients with AEs received
bilateral blocks (6/8) and all except one were female. Of
those with AEs, 50% were elderly. One patient with history
of pseudoseizures had a typical episode after 5% Lidocaine
and an electroencephalogram done during the episode
showed no evidence of epileptic activity. Three patients
given 5% Lidocaine reported dizziness and elevation in
blood pressure compared to the pre-procedural measure-
ment. Our 71-year-old female had the most significant
elevation in BP from 133/71 at baseline, to 209/84, which
came back to normal levels (129/90) almost 2 h after the
procedure. Our 73-year-old subject recorded a baseline BP
of 114/69, which after the procedure (during her pseudo-
seizure), was elevated to 140–150/70 transiently, but
resumed normal values within 45 min. Our third patient
had a minor elevation in blood pressure only. None of the
patients injected 1% Lidocaine had any elevation in blood
pressure.
We report no statistically significant correlation between
Lidocaine dose and occurrence of adverse effects, though
there was a slight trend toward more adverse effects in the
Lidocaine 5% group (p = 0.072) compared to the Lido-
caine 1% group (p = 0.33). There was no significant cor-
relation between the occurrence of AEs and age, gender or
bilateral versus unilateral injections. All our subjects,
including those who had side effects reported complete
pain relief for at least 3–7 days, the maximum period of
pain relief being 33 days.
Discussion
To our knowledge, this is the first report comparing 1, 2
and 5% Lidocaine use in a homogenous group of patients
with a single diagnosis and where the same type of injec-
tion and steroid was used for all the procedures. Ours is the
first large case series report of experience with 5% Lido-
caine for ONB. Choi et al. [7] were the first to describe the
use of 5% Lidocaine for ONB and suggested that it may
have a more long-lasting effect than 1 or 2% injections.
Choi et al. study did not report on any side effects and their








No. of subjects 69 18 29
Total no. of blocks 173 31 111
Unilateral 51 13 17
Bilateral 61 9 47
Age in years, mean (SD) 53 (19) 58.2 (17.5) 50.3 (19.7)
Female, no. (%) 54 (78) 15 (83.3) 19 (79)
Race, no. (%)
White 35 (51) 8 (44) 19 (66)
Hispanic 25 (36) 7 (39) 6 (21)
African American 2 (0.03) 3 (17) 4 (14)
Asian 7 (10) 0 0
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their experience with 5% Lidocaine since then. We started
using 5% Lidocaine in our headache clinics in patients who
had recurrent symptoms in spite of ONB with 1 and 2%
Lidocaine. We advanced their treatment to 5% Lidocaine
with the thought that this may produce prolonged effects as
reported by Choi et al. Only 3 patients reported symptoms
out of 173 ONB blocks with Lidocaine 1%, which is
consistent with other studies (Table 3). Our study showed a
very slight (3%) increase in AE with 5% Lidocaine com-
pared to 1% Lidocaine. Among the patients who had
adverse effects with 1% Lidocaine, two were being injected
for the first time and one patient was receiving an ONB for
the second time. Among the patients who had adverse
effects with 5% Lidocaine, two had previously received
ONB with 1%, however, three patients were receiving
ONB for the first time. Furthermore, of the 89 patients
injected, 15 received ONB for the first time, of which 5
subjects had side effects. Of the 74 patients who received
an ONB more than once, 3 had side effects. This data
indicates that patients receiving injections for the first time
were more likely to experience adverse effects. We spec-
ulate that repeated injections might have produced a tol-
erance, reducing the likelihood of adverse effects.
Based on our data which shows that none of the patients
receiving 2% Lidocaine had AEs, this may seem to be the
‘‘ideal’’ strength to use, but we cannot make that conclu-
sion since the number of patients in the 2% Lidocaine
group was much smaller than the other two groups. We
suggest that there are multiple factors leading to adverse
effects, with concentration being perhaps relatively minor,
since some of our patients had AEs with 1% but tolerated
5% Lidocaine injection very well.
Dizziness is a common side effect with local Lidocaine
injections and the most commonly reported adverse effect
in our case series (Table 3). Naja et al. [8] reported 47
patients who underwent ONB with a combination of
Lidocaine, epinephrine, fentanyl, and clonidine of which 2
reported dizziness. Anthony et al. [9, 10] had the large
series of 180 patients and they reported 8 patients with
dizziness and gait uncertainty with ONB using 1% Lido-
caine and 160 mg MP. Saadah et al. [11] also had a large
study in which a total of 188 ONB injections were done
with 1% Lidocaine and 12 mg Betamethasone and reported
dizziness for 1–2 h and injection site soreness for
1–2 days.
The side effect profile for Lidocaine when used for ONB
was not listed in the Pharmaceutical Drug Reference, and
on reviewing the package insert we did find dizziness,
confusion, bradycardia and hypotension listed, but not
elevation in blood pressure. In our study, the concentration
and type of steroid remained the same for all patients, and
therefore we believe that steroids were not likely the cau-
sation factor for the AEs, but this cannot be fully confirmed
without comparing patients who received Lidocaine alone
to those with a combination of Lidocaine and steroids.
Steroids have a mineral corticoid action and the inter-
mittent hypertension developing within the few minutes of
injection may be related to this and also given the close
proximity of GON with the artery raises the possibility of
arterial puncture, however, no reports were found on lit-
erature search. Patients who receive multiple blocks may
need to be monitored for the development of a very rare
side effect, Cushing’s syndrome. Lavin et al. [12] reported
a case of 39-year-old female who had six bilateral GON
blocks over a period of 3 months developed signs of
Cushing’s syndrome with intermittent hypertension, severe
muscle weakness, and fluid retention. Slurring of speech
was observed in all our patients who developed intermittent
hypertension and dizziness. Slurred speech is not listed as a
side effect of local injection of Lidocaine or Depo-medrol
in the package inserts.
Leinisch-Dahlke et al. [13] injected 15 tension headache
patients, with prilocaine 1% and dexamethasone, and
reported injection site pain in 3 and bradycardia in 1 patient
during neck palpation. Ambrosini et al. reported local pain
in two patients after injecting 13 patients for cluster
Table 2 Adverse effect
description for 1, 2, and 5%
Lidocaine
Age Sex Side Side effect description
5% Lidocaine
72 F R Dizziness, blurring of vision, slurred speech
27 F B Dizziness, slurred speech, lightheaded,
and extreme numbness of her head
71 F B Hypertension, slurred speech, numbness, asterixis
45 F R Hypertension, dizzy, lightheaded
73 F B Hypertension, pseudoseizure
1% Lidocaine
80 F B Dizziness, blurring of vision, slurred speech
47 M B Headache, tense and tight neck muscles
49 F B Lightheaded
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headaches with 2% Lidocaine. None of our patients
reported injection site pain. Other rare side effects reported
in literature with ONB include alopecia. Afridi et al. [14]
reported focal alopecia in 2 patients out of 116 injections
with 2% Lidocaine and 80 mg methylprednisone. Cutane-
ous atrophy after corticosteroid injection ranges from 1 to
14% of patients and resolution is reported to occur in
6–7 months and may persist for 24 months[15, 16]. None
of our patients reported these side effects, even though
many of them had serial injections. To prevent this com-
plication, injections should avoid leakage into the dermis.
Previous studies have failed to show that combining
Lidocaine with steroid provided added benefit for ONB
when compared to Lidocaine alone [17, 18]. However,
these studies have different patient population, different
steroid, different concentration, and there was lack of
uniformity of technique. All our patients, even those who
had adverse reaction to the injection reported response to
injection. One patient who had received 1% Lidocaine and
reported dizziness went onto receive 5% Lidocaine without
any adverse effects. The data from this study show that
Lidocaine injections are generally safe and well-tolerated,
the commonest side effect being dizziness.
The clinical implication of distinguishing the side effect
profile of different strengths of Lidocaine includes proper
choice of subjects and proper pre-procedure instructions.
We observed that all our patients who had side effects were
on an empty stomach, and therefore we suggest the patients
not to fast prior to undergoing this procedure. Based on our
observation that most patients who had side effects had
received bilateral injections at the same time, we now
recommend that patients, who need bilateral injections,
receive them at least 15–30 min apart, or on different
visits. We also suggest that vital signs should be routinely
monitored for 30 min post-procedure.
Our study limitations include the small sample size, the
lack of a patient group who received only Lidocaine
injections without steroids, and that we did not investigate
disease parameters (disease duration and severity of pain)
or treatment outcomes in our patients.
In conclusion, our study will also help remind the cli-
nician that several types of Lidocaine injections are
available for headache patient, and it is important to sep-
arate each element to tailor individualized treatment. Fur-
ther studies comparing different concentration of Lidocaine
with and without additional steroids are needed to address
Table 3 Review of occipital nerve block adverse events in literature
Study Population Side effects Medication injected
Saadah, Taylor [11] Total 188 injections: (post-




1–2 h, injection site
soreness for 1–2 days
10 mL 1% LC ? 12 mg BM, divided
among ONs. Total volume 12 cc per
injection set
Anthony [9] Cervicogenic HA
LC ? MP to 180 pts
MP to 180 pts
LC during HA, 50 pts
IM MP alone




3–4 mL 1% LC ? 160 mg MP
(4 mL) as separate injection (in
thirds, with the needle directed
straight, medially, and laterally)
5 min later or, if pt was ictal, after
the LC aborted the HA. Area
massaged after steroid injection
Leinisch-Dahlke et al. [13] Tension, failed or intolerant to
preventive therapy. 15 patients
Injection site pain in 3.
Bradycardia 36 BPM
5 mL 1% prilocaine ? 4 mg DM,
total volume 6 mL per injection set
Ambrosini et al. [18] Cluster, 10 pts Local pain in 2 patients 0.5 mL 2% LC ? 17.72 mg BM
(12.46 BM dipropionate, long
acting, 5.26 mg BM disodium
phosphate), total volume 3 mL
Afridi et al. [14] Total 116 injections Migraine,
57; Cluster; 22; New HA, 16;
HC, 10.
2 pts—focal alopecia 3 mL 2% LC ? 80 mg MP
Naja et al. [8] Cervicogenic HA:47 pts received
mean 5.3 (up to 13) injections
2 pts—dizziness 3 mL of the following 10 mL solution
to each nerve: 3 mL 2% LC, 3 mL
2% LC ? epi, 2.5 mL 0.5% BP,
0.5 mL fentanyl 50 lg/mL, 1 mL
clonidine 150 lg/mL
B bilateral, BP bupivicaine, BM Betamethasone, HA headache, IM intramuscular, LC lidocaine, LON lesser occipital nerve, MP methylpred-
nisolone, N none, SMO symptomatic medication overuse, TC triamcinolone
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differences in long-term and adverse effect profile of this
procedure.
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